Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000628 · ClinicalTrials.gov registry record · Phase 1
A Pharmacokinetic Study of L-697,661 Alone and in Combination With Zidovudine
A Phase 1 study of HIV Infections, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
- 5
- Study locations
NCT00000628: Completed Phase 1 study of HIV Infections, sponsored by Merck Sharp & Dohme.
NCT00000628 is a Phase 1 study of HIV Infections that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 27 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (94% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000628, a Phase 1 study of HIV Infections, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
- 5
- Study locations
Study Summary
Part 1: To study the potential safety and pharmacokinetic (blood level) effects of zidovudine (AZT) on L-697,661; to obtain additional pharmacokinetic information in humans with L-697,661; to study the effect of L-697,661 on hepatic enzyme induction. Part 2: To begin a study of the antiviral activity of L-697,661. L-697,661 is a newly identified compound that inhibits HIV replication (reproduction and growth) in cell culture. It works together with AZT against HIV.
Conditions Studied
Interventions
- DRUG Zidovudine
- DRUG L-697,661
Study Locations (5)
Illinois
- Northwestern Univ Med School - Chicago
- Rush Presbyterian - Saint Luke's Med Ctr - Chicago
California
- San Francisco Gen Hosp - San Francisco
Colorado
- Univ of Colorado Health Ctr / Denver Gen Hosp - Denver
Washington
- Univ of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Phase | Phase 1 |
What the finished NCT00000628 record still lists
NCT00000628 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (94% lower).
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Zidovudine is the first listed.
NCT00000628 lists 5 locations in 4 states (Illinois, California, Colorado).
Frequently Asked Questions
What is clinical trial NCT00000628 about?
NCT00000628 is a clinical study titled "A Pharmacokinetic Study of L-697,661 Alone and in Combination With Zidovudine". Part 1: To study the potential safety and pharmacokinetic (blood level) effects of zidovudine (AZT) on L-697,661; to obtain additional pharmacokinetic information in humans with L-697,661; to study the effect of L-697,661 on hepatic enzyme induction. Part 2: To begin a study of the antiviral activit...
What is the current status of trial NCT00000628?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants.
What conditions does trial NCT00000628 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00000628?
The interventions under investigation include: Zidovudine (DRUG), L-697,661 (DRUG).
Who is sponsoring clinical trial NCT00000628?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00000628 being conducted?
This trial has 5 study locations across California, Colorado, Illinois, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00000628's enrollment target sits among peer trials
27 450th of 542 higher than 87 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CAR-T Cells for HIV Infection
RECRUITING · Phase 1
-
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
RECRUITING · Phase 1
-
Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706
RECRUITING · Phase 1
-
Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics
RECRUITING · Phase 1
-
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
RECRUITING · Phase 1
-
First Time in Human Study of Long Acting VH4524184 Formulations
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery